AV-101
DrugOral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Other names: L-4-chlorokynurenine
NCT Number: NCT03078322
The study will evaluate the safety and efficacy of AV-101.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
VistaGen Investigational Site, Garden Grove, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Other names: L-4-chlorokynurenine
Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Time frame: 2 weeks
Depression questionnaire
Time frame: 2 weeks
50% improvement on MADRS-10
Time frame: 2 weeks
Also include EKG, labs etc.
VistaGen Therapeutics, Inc.
Industry
Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)
Acronym: ELEVATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial Details